Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.
Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsJonae Barnes - Senior Vice President of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback